Try our beta test site
Trial record 1 of 6 for:    AP26113
Previous Study | Return to List | Next Study

A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2014 by Ariad Pharmaceuticals.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Ariad Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01449461
First received: September 30, 2011
Last updated: August 21, 2014
Last verified: August 2014